Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CETP | P11597 | 4/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2915831 | 1.00 | CYP2C19 (0.50) | CYP2C19CETPTBXAS1CYP4F2CYP4A11 | |
| SCHEMBL30701364 | 1.00 | CYP2C19 (0.50) | CYP2C19CETPTBXAS1CYP4F2CYP4A11 | |
| SCHEMBL8034730 | 0.98 | TBXAS1 (0.50) | CYP2C19CETPTBXAS1CYP4F2CYP4A11 | |
| SCHEMBL7258608 | 0.98 | TBXAS1 (0.50) | CYP2C19CETPTBXAS1CYP4F2CYP4A11 | |
| SCHEMBL887733 | 0.98 | TBXAS1 (0.50) | CYP2C19CETPTBXAS1CYP4F2CYP4A11 | |
| SCHEMBL1264712 | 0.98 | TBXAS1 (0.50) | CYP2C19CETPTBXAS1CYP4F2CYP4A11 | |
| SCHEMBL482363 | 0.98 | TBXAS1 (0.50) | CYP2C19CETPTBXAS1CYP4F2CYP4A11 | |
| SCHEMBL887781 | 0.98 | TBXAS1 (0.50) | CYP2C19CETPTBXAS1CYP4F2CYP4A11 | |
| Ammonia Solution, Strong SCHEMBL7718356 | 0.98 | CYP2C19 (0.48) | CYP2C19CETPTBXAS1CYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL10584019 | 0.98 | TBXAS1 (0.49) | CYP2C19CETPTBXAS1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| CN-100569944-C | Production of polyketides and other natural products | BIOTICA TECH LTD (GB) | 2009-12-16 | — | — | CN | claimed |
| CN-101302225-A | Production of polyketides and other natural products | BIOTICA TECH LTD (GB) | 2008-11-12 | — | — | CN | claimed |
| CN-101302550-A | Production of polyketides and other natural products | BIOTICA TECH LTD (GB) | 2008-11-12 | — | — | CN | claimed |
| US-7335405-B2 | Nematic liquid crystal mixtures for use in bistable display devices | NEMOPTIC (FR) | 2008-02-26 | — | — | US | claimed |
| EP-1740181-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-10 | — | — | EP | claimed |
| US-20060249708-A1 | Nematic liquid crystal mixtures for use in bistable display devices | CDC PROPRIETE INTELLECTUELLE (FR) | 2006-11-09 | — | — | US | claimed |
| WO-2005102342-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
| CN-1668741-A | Production of polyketides and other natural products | BIOTICA TECH LTD (GB) | 2005-09-14 | — | — | CN | claimed |
| US-6071538-A | TRANSPORTATION ACROSS CELL MEMBRANE OR LIPID BILAYER | EMISPHERE TECHNOLOGIES, INC. (US) | 2000-06-06 | — | — | US | claimed |
| EP-0216671-A1 | Mixture of liquid crystals containing a Schiff base | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1987-04-01 | — | — | EP | claimed |
| EP-0033947-B2 | LIQUID CRYSTAL DISPLAY ELEMENT | KABUSHIKI KAISHA TOSHIBA (JP) | 1987-01-14 | — | — | EP | claimed |
| EP-0033947-B1 | LIQUID CRYSTAL DISPLAY ELEMENT | KABUSHIKI KAISHA TOSHIBA (JP) | 1983-09-21 | — | — | EP | claimed |
| EP-0025119-B1 | NEMATIC CRYSTALLINE-LIQUID 5-ALKYL-2-(4-ACYLOXYPHENYL)-PYRIMIDINES FOR OPTO-ELECTRONIC ARRANGEMENTS AND PROCESS FOR THEIR PREPARATION | VEB Werk Für Fernsehelektronik im VEB Kombinat Mikroelektronik (DD) | 1983-05-25 | — | — | EP | claimed |
| US-12564879-B2 | Copper paste for joining, method for manufacturing joined body, and joined body | RESONAC CORPORATION (JP) | 2026-03-03 | — | — | US | disclosed |
| US-20250387833-A1 | METHOD FOR MANUFACTURING CONDUCTIVE VIA-CONTAINING SUBSTRATE, CONDUCTIVE VIA-CONTAINING SUBSTRATE, AND METAL PASTE | RESONAC CORP (JP) | 2025-12-25 | — | — | US | disclosed |
| US-20250293091-A1 | METHOD FOR PRODUCING SUBSTRATE HAVING THROUGH-SILICON VIAS, SUBSTRATE HAVING THROUGH-SILICON VIAS, AND COPPER PASTE FOR THROUGH-SILICON VIA FORMATION | RESONAC CORPORATION (JP) | 2025-09-18 | — | — | US | disclosed |
| WO-1988002364-A2 | PROCESS FOR THE PRODUCTION OF ETHANE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1988-04-07 | — | — | WO | disclosed |
| US-4723005-A | CONTAINING POLARIZED CYANO OR HALOGEN SUBSTITUENTS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-02-02 | — | — | US | disclosed |
| EP-0216671-A1 | Mixture of liquid crystals containing a Schiff base | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1987-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387833-A1 | METHOD FOR MANUFACTURING CONDUCTIVE VIA-CONTAINING SUBSTRATE, CONDUCTIVE VIA-CONTAINING SUBSTRATE, AND METAL PASTE | C5, C9, CUTA | CYP2C19 979/4885CETP 1026/4885TBXAS1 4583/4885 |
| US-12564879-B2 | Copper paste for joining, method for manufacturing joined body, and joined body | DCX, DNAJA2, DNAJA1 | CYP2C19 495/4885CETP 252/4885TBXAS1 2272/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | CYP2C19 574/4885CETP 3835/4885TBXAS1 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.